The possibility of limiting pro-inflammatory cytokine response after disease onset, by anti-inflammatory molecules targeting TLR4-MD2, could represent a useful adjunct for the treatment of periodontal disease, in which it is important to eradicate infection but also to stem the negative effects of the LPS released by periodontopathic bacteria. Here, LY96 is linked to periodontal disorder.